Modality
mAb
MOA
FXIai
Target
Nectin-4
Pathway
Tau
Ewing Sarcoma
Development Pipeline
Preclinical
~Apr 2014
→ ~Jul 2015
Phase 1
~Oct 2015
→ ~Jan 2017
Phase 2
Apr 2017
→ Aug 2030
Phase 2Current
NCT06385724
1,807 pts·Ewing Sarcoma
2017-04→2025-09·Terminated
NCT04974355
2,447 pts·Ewing Sarcoma
2023-01→2030-08·Completed
4,254 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-09-137mo agoPh2 Data· Ewing Sarcoma
2030-08-134.4y awayPh2 Data· Ewing Sarcoma
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2
Termina…
P2
Complet…
Catalysts
Ph2 Data
2025-09-13 · 7mo ago
Ewing Sarcoma
Ph2 Data
2030-08-13 · 4.4y away
Ewing Sarcoma
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06385724 | Phase 2 | Ewing Sarcoma | Terminated | 1807 | OS |
| NCT04974355 | Phase 2 | Ewing Sarcoma | Completed | 2447 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-6360 | Novartis | Approved | CD38 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| Semazasiran | BeiGene | Phase 1 | PD-1 | |
| ION-3857 | Ionis | Preclinical | Nectin-4 |